Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $5.00 target price on the stock.
Separately, D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday.
Read Our Latest Analysis on Invivyd
Invivyd Stock Down 9.1%
Shares of IVVD traded down $0.07 during trading on Thursday, reaching $0.73. 10,196,338 shares of the company traded hands, compared to its average volume of 4,561,731. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74. The stock has a market cap of $87.15 million, a PE ratio of -0.61 and a beta of 0.63. The stock has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $0.76.
Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $34.45 million. Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. On average, equities research analysts predict that Invivyd will post -1.64 EPS for the current year.
Institutional Trading of Invivyd
Hedge funds have recently made changes to their positions in the stock. Nuveen LLC acquired a new position in Invivyd during the first quarter worth about $65,000. Invesco Ltd. lifted its holdings in shares of Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after buying an additional 71,485 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Invivyd during the 1st quarter valued at about $66,000. Jane Street Group LLC lifted its holdings in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after buying an additional 87,358 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after buying an additional 9,207 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company's stock.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
